FEDERAL COURT OF AUSTRALIA
Eli Lilly and Company v Generic Health Pty Ltd [2013] FCA 1254
Citation: Eli Lilly and Company v Generic Health Pty Ltd [2013] FCA 1254 Parties: ELI LILLY AND COMPANY and ELI LILLY AUSTRALIA PTY LTD (ACN 000 233 992) v GENERIC HEALTH PTY LTD (ACN 110 617 859) File number: NSD 1902 of 2013 Judge: NICHOLAS J Date of judgment: 26 November 2013 Catchwords: PATENTS – threatened infringement of pharmaceutical patent for raloxifene – claim to raloxifene in particulate form with specified mean particle size – whether interlocutory injunction should be granted – whether prima facie case for final relief – strength of infringement and invalidity cases – whether mandatory interlocutory injunction should be granted requiring respondent to withdraw application for listing of its generic raloxifene products on the Schedule of Pharmaceutical Benefits – consideration of balance of convenience – significance of mandatory price reduction under Pharmaceutical Benefits Scheme – difficulties in quantifying and apportioning applicants’ losses in circumstances where mandatory price reduction triggered and generic suppliers enter market for raloxifene products.
Held: Interlocutory injunctions granted.
Legislation: Evidence Act 1990 (Cth) s 135
Intellectual Property Laws Amendment (Raising the Bar) Act2012 (Cth)
National Health Act (1953) (Cth)
Patents Act 1990 (Cth) ss 13, 125, 126 and 127Cases cited: American Cyanamid Co v Ethicon Ltd [1975] AC 396
Australian Broadcasting Corporation v O’Neill (2006) 227 CLR 57
Beecham Group Ltd v Bristol Laboratories Pty Ltd (1968) 118 CLR 618
Flexible Steel Lacing Company v Beltreco Ltd (2000) 49 IPR 331
Jupiters Ltd v Neurizon Pty Ltd (2005) 222 ALR 155
Kirin Amgen Inc v Hoechst Marion Russell Ltd (2004) 64 IPR 444
Lockwood Security Products Pty Limited v Doric Products Pty Limited (2004) 217 CLR 274
Minnesota Mining and Manufacturing Company v Beiersdorf (Australia) Limited (1980) 144 CLR 253
Samsung Electronics Co Ltd v Apple Inc (2011) 286 ALR 257Date of hearing: 12 November 2013 Place: Sydney Division: GENERAL DIVISION Category: Catchwords Number of paragraphs: 82 Counsel for the Applicants: Mr BN Caine SC with Mr JS Cooke Solicitor for the Applicants: Wrays Lawyers Counsel for the Respondent: Mr R Lancaster SC with Mr L Merrick Solicitor for the Respondent: Corrs Chambers Westgarth
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
NSD 1902 of 2013
BETWEEN: ELI LILLY AND COMPANY
First ApplicantELI LILLY AUSTRALIA PTY LTD (ACN 000 233 992)
Second ApplicantAND: GENERIC HEALTH PTY LTD (ACN 110 617 859)
Respondent
JUDGE:
NICHOLAS J
DATE OF ORDER:
26 November 2013
WHERE MADE:
SYDNEY
THE COURT NOTES:
1.Upon the applicants, by their counsel, giving the usual undertaking as to damages, namely to:
(a)submit to such order (if any) as the Court may consider to be just for the payment of compensation, to be assessed by the Court or as it may direct, to any person, whether or not a party, adversely affected by the operation of these orders (or any continuation of them and whether with or…
Keep reading for free
Create a free CaseChat account to read Eli Lilly and Company v Generic Health Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2013] FCA 1254
- Decision Date
CaseChat Overview and Summary
The court considered the scientific evidence provided by the parties' experts, notably Dr Luk, Professor Polli, and Professor Buckton. Dr Luk's affidavits were crucial in assessing the particle size measurements of the raloxifene in the samples provided by Generic Health. The court needed to determine the reliability and relevance of Dr Luk's test results and protocols, as well as the objections raised by the respondent regarding the admissibility of certain affidavits. The court also examined the opinions of Professor Polli and Professor Buckton, which provided differing views on the interpretation and significance of the particle size data.
In its reasoning, the court found that the applicants had demonstrated a prima facie case for final relief. The evidence presented by Dr Luk was deemed reliable and relevant, supporting the applicants' claims regarding the particle size specifications of the raloxifene. The court accepted that the respondent's product did not meet the critical particle size criteria outlined in the patents, thereby establishing a likelihood of infringement. The court ruled in favour of the applicants, granting the sought relief against the respondent's alleged infringement.
The final orders included an injunction preventing Generic Health from manufacturing, using, or selling the product that infringed the patents, as well as an order for the delivery up of any infringing products. The court also ordered that the matter be listed for further directions to address the remaining issues in the proceeding.
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi